10 research outputs found

    Dose patterns in commercially insured subjects chronically exposed to opioids: a large cohort study in the United States

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>Little data exist on how opioid doses vary with the length of exposure among chronic opioid users.</p> <p>Methods</p> <p>To characterize the change in the dosage of opioids over time, a retrospective cohort study using the PharMetrics database for the years 1999 through 2008 was conducted. Individuals exposed to opioids in 2000 who had 2 opioid dispensings at least 6 months apart and were opioid naive (did not receive any opioid 6 month before their exposure in 2000) were included. The date of the first dispensing in 2000 was defined as the index date and the dispensing had to be for a strong and full agonist opioid. All opioid doses were converted to oral morphine equivalent doses. Exposure was classified as continuous or intermittent. Mean, median, interquartile range, and 95<sup>th </sup>percentile of opioid dose over 6-month periods, as well as the percentage of subjects who ever received a high or very high opioid dose, were calculated.</p> <p>Results</p> <p>Among the 48,986 subjects, the mean age was 44.5 years and 54.5% were women. Intermittent exposure was observed in 99% of subjects; continuous exposure was observed in 1% of subjects. The mean duration of exposure for the subjects who were continuously exposed to opioids was 477 days. In subjects with no cancer diagnosis who were continuously exposed to opioids, the mean, 25<sup>th</sup>, 50<sup>th</sup>, and 75<sup>th </sup>percentile of dose was stable during the first 2 years of use, but the 95<sup>th </sup>percentile increased. Seven percent of them were exposed to doses of 180 mg or more of morphine at some point.</p> <p>Conclusions</p> <p>Dose escalation is uncommon in subjects with intermittent exposure to opioids. For subjects with continuous exposure to opioids who have cancer, doses rise substantially with time. For those without cancer, doses remain relatively stable for the first 2 years of use, but subsequently increase. Seven percent of subjects with no cancer diagnosis will be exposed to daily doses of 180 mg or more of morphine equivalent at some point.</p

    [29-3-25, Colombes, rugby, match Paris-Londres] : [photographie de presse] / [Agence Rol]

    No full text
    Référence bibliographique : Rol, 99533Appartient à l’ensemble documentaire : Pho20RolImage de press

    Inferring pregnancy episodes and outcomes within a network of observational databases

    No full text
    <div><p>Administrative claims and electronic health records are valuable resources for evaluating pharmaceutical effects during pregnancy. However, direct measures of gestational age are generally not available. Establishing a reliable approach to infer the duration and outcome of a pregnancy could improve pharmacovigilance activities. We developed and applied an algorithm to define pregnancy episodes in four observational databases: three US-based claims databases: Truven MarketScan<sup>®</sup> Commercial Claims and Encounters (CCAE), Truven MarketScan<sup>®</sup> Multi-state Medicaid (MDCD), and the Optum ClinFormatics<sup>®</sup> (Optum) database and one non-US database, the United Kingdom (UK) based Clinical Practice Research Datalink (CPRD). Pregnancy outcomes were classified as live births, stillbirths, abortions and ectopic pregnancies. Start dates were estimated using a derived hierarchy of available pregnancy markers, including records such as last menstrual period and nuchal ultrasound dates. Validation included clinical adjudication of 700 electronic Optum and CPRD pregnancy episode profiles to assess the operating characteristics of the algorithm, and a comparison of the algorithm’s Optum pregnancy start estimates to starts based on dates of assisted conception procedures. Distributions of pregnancy outcome types were similar across all four data sources and pregnancy episode lengths found were as expected for all outcomes, excepting term lengths in episodes that used amenorrhea and urine pregnancy tests for start estimation. Validation survey results found highest agreement between reviewer chosen and algorithm operating characteristics for questions assessing pregnancy status and accuracy of outcome category with 99–100% agreement for Optum and CPRD. Outcome date agreement within seven days in either direction ranged from 95–100%, while start date agreement within seven days in either direction ranged from 90–97%. In Optum validation sensitivity analysis, a total of 73% of algorithm estimated starts for live births were in agreement with fertility procedure estimated starts within two weeks in either direction; ectopic pregnancy 77%, stillbirth 47%, and abortion 36%. An algorithm to infer live birth and ectopic pregnancy episodes and outcomes can be applied to multiple observational databases with acceptable accuracy for further epidemiologic research. Less accuracy was found for start date estimations in stillbirth and abortion outcomes in our sensitivity analysis, which may be expected given the nature of the outcomes.</p></div

    Distribution of pregnancy algorithm start estimation method groups for all pregnancy episodes from each data source (CPRD, Optum, Truven CCAE, and Truven MDCD) by outcome (abortion, ectopic pregnancy, live birth, and stillbirth).

    No full text
    <p>Legend for start estimation methods in stacked bars: Group 1 = last menstrual period, gestational age record, fertility procedure; Group 2 = alpha-fetoprotein test, nuchal ultrasound; Group 3 = amenorrhea record, urine pregnancy test record; Group 4 = average gestational age estimate.</p

    Illustration of steps performed by pregnancy episode algorithm for sample patient with three classified pregnancy episodes and estimated start dates.

    No full text
    <p>LB: Live birth; SB: Stillbirth; ECT: Ectopic pregnancy; SA: Abortion; PCONF: Pregnancy confirmation marker; ULS: Nuchal ultrasound; AMEN: Amenorrhea record.</p

    Optum validation sensitivity analysis: Algorithm chosen pregnancy start categorized by difference in either direction from infertility procedure derived start.

    No full text
    <p>Optum validation sensitivity analysis: Algorithm chosen pregnancy start categorized by difference in either direction from infertility procedure derived start.</p
    corecore